Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer

Trial Profile

Nivolumab and Ipilimumab and Radiation Therapy in Microsatellite Stable (MSS) and Microsatellite Instability (MSI) High Colorectal and Pancreatic Cancer

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Adenocarcinoma; Colorectal cancer; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2019 Results (n=40) assessing efficacy of ipilimumab and nivolumab with radiation in metastatic colorectal adenocarcinoma, presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
    • 19 Jan 2019 Results assessing ipilimumab and nivolumab with radiation in metastatic pancreatic adenocarcinoma (n=22) presented at the 2019 Gastrointestinal Cancers Symposium
    • 29 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top